Achelios Therapeutics, Inc., is a Chapel Hill, North Carolina based specialty pharmaceutical company with primary focus on “New Therapeutic Entity” (NTE) development for the treatment of pain and inflammation by topically delivered medications. Achelios Therapeutics is currently focusing its resources on its most advanced product, TOPOFEN™, for the indication of acute migraines. We believe we have found the solution to a problem that has plagued other industry players for a number of years: how to successfully transfer efficacious amounts of active non-steroidal anti-inflammatory drugs (NSAIDs) through the dermis to the target tissue.
The medications developed by Achelios Therapeutics Inc., greatly enhance the permeation of selective agents across human skin. Clinical results to date show that our drug formulations offer superior skin permeation (between 4 and 9 times) than that of leading commercial brands. ACHETOGEL™ formulations have the advantage of bypassing first-pass metabolism by the renal and hepatic systems, thereby effectively minimizing systemic exposure. ACHETOGEL™ is a biodegradable formulation that is thermodynamically stable, resistant to microbial contamination, and insensitive to moisture.
We are building a strong drug development portfolio with patent-protected pharmaceutical products, compositions, and/or method-of-use. Patent protection on topically delivered formulations will be derived through internally generated concepts and by in-licensing third party intellectual property. We plan to pursue unique formulations of other NSAIDs for the indications of migraine prophylaxis, osteoarthritis, sprains and strains, and Temporomandibular joint (TMJ) disorders.
Achelios Therapeutics, Inc. is backed by a management team and board of directors that possess with a deep understanding of drug discovery, formulation development, clinical development, and business development experience